First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults

Current Opinion in Oncology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Ottmann, Oliver G ^a   Pfeifer, Heike ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Bcr abl mutations; Minimal residual disease; Philadelphia chromosome; Stem cell transplantation; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; DASATINIB; DEXAMETHASONE; IMATINIB; NILOTINIB; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GROUPS BY AGE; HUMAN; IMMUNOTHERAPY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MUTATION; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STEM CELL TRANSPLANTATION; THIAZOLES; TREATMENT OUTCOME;

EID: 68049111583     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000357476.43164.6b     Document Type: Short Survey

References (26)

1. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15:21-36.
2. Gleissner B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99:1536-1543.
3. Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109:2068-2076.
4. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood 2007; 109:3676-3678.
5. Foà R, Vitale A, Guarini A, et al. Front-line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 Study. Blood 2008; 112:119a. [Abstract 305].
6. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24:460-466.
7. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006; 108:1469-1477.
8. Thomas DA, Kantarjian HM, Cortes J, et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 2008; 112:1008a. [Abstract 2931].
9. Chalandon Y, Thomas X, Hayette S, et al. First results of the GRAAPH-2005 Study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia. Blood 2008; 112:11a. [Abstract 12].
10. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396-4407.
11. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547-561.
12. de Labarthe A, Rousselot P, Huguet-Rigal F, et al., Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109:1408-1413.
13. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19:1509-1516.
14. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20:1526-1532.
15. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105:3449-3457.
16. Ravandi F, Thomas DA, Kantarjian HM, et al. Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 2008; 112:1005a. [Abstract 2921].
17. Rousselot P, Cayuela JM, Recher C, et al. Dasatinib (Sprycel®) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL)). Blood 2008; 112:1004a. [Abstract 2920].
18. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99:1860-1862.
19. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99:3472-3475.
20. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. Clin Cancer Res 2006; 12:7374-7379.
21. Hofmann WK, Komor M, Wassmann B, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003; 102:659-661.
22. Soverini S, Martinelli G, Vitale A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor bcr-abl kinase domain mutations at low levels at the time of diagnosis - a report by the GIMEMA ALL Working Party. Blood 2008; 112:268a. [Abstract 722].
23. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110:727-734.
24. Mizuta S, Yanada M, Sugiura I, et al. Efficacy of allogeneic hematopoietic stem cell transplantation during first complete remission following imatinib-combined chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2008; 112:176a. [Abstract 462].
25. Pfeifer H, Wystub S, Wassmann B, et al. Minimal residual disease and mutational status prior to and after SCT for patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2008; 112:261a. [Abstract 702].
26. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005; 106:458-463.